Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”d[ESMO Open 9 (2024) 103703] : corrigendum - Hofheinz, Ralf-Dieter; Herrle, Florian; Dechow, T.; von Weikersthal, L. F.; Welslau, M.; Lettmaier, S.; Burkart, C.; Kubicka, S.; Kochen, L.; Merx, Kirsten; Krause, K.; Ebert, Matthias; et al. (ESMO open, 2025)
Online verfügbar: 16. Dezember 2024, Artikelversion: 20. Februar 2025